Liver fibrosis and CD206

ALT, alanine aminotransferase BAMBI, BMP and Activin Membrane-bound Inhibitor CD206+ macrophages DAA, direct-acting antiviral DC, dendritic cell FFPE, formalin-fixed paraffin-embedded GM-CSF GM-CSF, granulocyte-macrophage colony-stimulating factor HCC, hepatocellular carcinoma HCV HIER, heat-induced epitope retrieval HSC, hepatic stellate cells ICS, intracellular cytokine staining Intrahepatic macrophages LPS, lipopolysaccharide LSM, liver stiffness measurement MS, multiple sclerosis NASH NASH, non-alcoholic steatohepatitis PBMCs, peripheral blood mononuclear cells RA, rheumatoid arthritis SVR, sustained virological response TCR, T cell receptor TMA, tissue microarray TNFα, tumour necrosis factor-α TSA, tyramide signal amplification anti-GM-CSF neutralizing antibody fibrosis moMΦs, monocyte-derived macrophage-like cells t-SNE, t-distributed stochastic neighbour embedding

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 22 08 2019
revised: 18 11 2019
accepted: 20 11 2019
entrez: 11 2 2020
pubmed: 11 2 2020
medline: 11 2 2020
Statut: epublish

Résumé

Chronic liver inflammation leads to fibrosis and cirrhosis and is associated with an accumulation of intrahepatic TNFα-secreting CD206 Liver immunohistochemistry and serum quantification were performed in patients with viral and non-viral-related liver disease to compare CD206 Using multiplex immunofluorescence and histo-cytometry, we show that highly fibrotic livers had a greater density of CD206 While the direct involvement of CD206 Liver fibrosis is a major driver of liver disease progression. Herein, we have shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) plays an important role in the development of liver fibrosis. Our findings support the use of anti-GM-CSF neutralising antibodies for the management of patients with chronic liver disease resulting from both viral and non-viral causes.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Chronic liver inflammation leads to fibrosis and cirrhosis and is associated with an accumulation of intrahepatic TNFα-secreting CD206
METHODS METHODS
Liver immunohistochemistry and serum quantification were performed in patients with viral and non-viral-related liver disease to compare CD206
RESULTS RESULTS
Using multiplex immunofluorescence and histo-cytometry, we show that highly fibrotic livers had a greater density of CD206
CONCLUSIONS CONCLUSIONS
While the direct involvement of CD206
LAY SUMMARY BACKGROUND
Liver fibrosis is a major driver of liver disease progression. Herein, we have shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) plays an important role in the development of liver fibrosis. Our findings support the use of anti-GM-CSF neutralising antibodies for the management of patients with chronic liver disease resulting from both viral and non-viral causes.

Identifiants

DOI: 10.1016/j.jhepr.2019.11.006 PMID: 32039403 PMC: PMC7005658
pubmed: 32039403
doi: 10.1016/j.jhepr.2019.11.006
pii: S2589-5559(19)30156-9
pii: 100062
pmc: PMC7005658
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100062

Informations de copyright

© 2019 The Author(s).

Références

Ann Rheum Dis. 2017 Jun;76(6):1020-1030
pubmed: 28213566
Blood. 1994 Sep 15;84(6):1737-46
pubmed: 7521686
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Front Biosci. 2007 Jan 01;12:800-15
pubmed: 17127321
PLoS One. 2013 Oct 21;8(10):e78045
pubmed: 24205083
J Hepatol. 2014 May;60(5):1090-6
pubmed: 24412603
J Exp Med. 2014 Jul 28;211(8):1533-49
pubmed: 25002752
J Exp Med. 1992 Jul 1;176(1):287-92
pubmed: 1613462
Immunopharmacol Immunotoxicol. 1998 Aug;20(3):373-82
pubmed: 9736442
J Exp Med. 2017 Nov 6;214(11):3293-3310
pubmed: 28978634
Nat Immunol. 2011 Jun;12(6):568-75
pubmed: 21516111
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
PLoS Pathog. 2013;9(4):e1003330
pubmed: 23633957
Blood. 2002 Jan 1;99(1):111-20
pubmed: 11756160
J Hepatol. 2007 Oct;47(4):598-607
pubmed: 17692984
Mod Pathol. 2014 Mar;27(3):352-60
pubmed: 23929266
Immunity. 2012 Jun 29;36(6):1031-46
pubmed: 22749353
J Exp Med. 2016 Nov 14;213(12):2793-2809
pubmed: 27799620
Gut. 2016 Oct;65(10):1744-53
pubmed: 26149491
Immunity. 2015 Sep 15;43(3):502-14
pubmed: 26341401
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
Acta Haematol. 1994;92(3):154-6
pubmed: 7871957
Rheumatol Int. 1995;14(5):177-82
pubmed: 7536953
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
J Biol Chem. 2014 Mar 7;289(10):7082-91
pubmed: 24448807
Immunity. 2016 Nov 15;45(5):963-973
pubmed: 27851925
Nat Rev Drug Discov. 2016 Dec 29;16(1):53-70
pubmed: 28031576
Nat Immunol. 2016 Jan;17(1):34-40
pubmed: 26681460
Sci Transl Med. 2015 Oct 21;7(310):310ra166
pubmed: 26491076
J Hepatol. 2014 Jan;60(1):197-209
pubmed: 23993913
J Hepatol. 1995 Feb;22(2):165-72
pubmed: 7790704
J Leukoc Biol. 1994 Mar;55(3):355-61
pubmed: 8120453
Trends Immunol. 2015 Oct;36(10):651-662
pubmed: 26431942
J Immunol. 2015 Mar 1;194(5):2424-38
pubmed: 25653427
Blood. 2012 Apr 12;119(15):3383-93
pubmed: 22323450
Gut. 2006 Mar;55(3):415-24
pubmed: 16174657
Gastroenterology. 2011 Oct;141(4):1220-30, 1230.e1-3
pubmed: 21726511
Scand J Gastroenterol. 1997 Sep;32(9):942-6
pubmed: 9299675
J Hepatol. 2017 Sep;67(3):490-500
pubmed: 28483682
Immunity. 2017 Feb 21;46(2):245-260
pubmed: 28228281
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4828-32
pubmed: 2191302
Blood. 2012 Sep 13;120(11):2259-68
pubmed: 22802339
Trends Immunol. 2002 Aug;23(8):403-8
pubmed: 12133803
Blood. 2019 Feb 14;133(7):697-709
pubmed: 30463995
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Cell Res. 2014 Dec;24(12):1387-402
pubmed: 25412660
PLoS One. 2013 Jun 11;8(6):e66898
pubmed: 23776701
PLoS One. 2013 Jun 03;8(6):e65251
pubmed: 23755201
J Exp Med. 2013 Sep 23;210(10):1977-92
pubmed: 24043763
Science. 1986 Apr 4;232(4746):61-5
pubmed: 2420009
Cancer Cell. 2012 Apr 17;21(4):504-16
pubmed: 22516259
Immunity. 2016 Sep 20;45(3):669-684
pubmed: 27637149
Nat Rev Immunol. 2017 Jan;17(1):49-59
pubmed: 27916979
Aliment Pharmacol Ther. 2016 Sep;44(6):638-43
pubmed: 27417456
Ann Rheum Dis. 2015 Jun;74(6):1058-64
pubmed: 24534756
Hepatology. 2013 Oct;58(4):1461-73
pubmed: 23553591
Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e117
pubmed: 26185773
Nat Immunol. 2011 Jun;12(6):560-7
pubmed: 21516112

Auteurs

Alfonso Tan-Garcia (A)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Fritz Lai (F)

Humanised Mouse Unit, Institute of Molecular and Cell Biology, ASTAR, 61 Biopolis Drive, Singapore 138673, Singapore.

Joe Poh Sheng Yeong (JP)

Department of Anatomical Pathology, Singapore General Hospital, Singapore.

Sergio E Irac (SE)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Pei Y Ng (PY)

Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.

Rasha Msallam (R)

Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.

Jeffrey Chun Tatt Lim (JC)

Department of Anatomical Pathology, Singapore General Hospital, Singapore.

Lu-En Wai (LE)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Christine Y L Tham (CYL)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Su P Choo (SP)

Department of Medical Oncology, National Cancer Centre, Singapore.

Tony Lim (T)

Department of Anatomical Pathology, Singapore General Hospital, Singapore.

Dan Y Young (DY)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Hospital, National University Health System, Singapore.

Roberta D'Ambrosio (R)

CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

Elisabetta Degasperi (E)

CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

Riccardo Perbellini (R)

CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

Evan Newell (E)

Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.
Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.

Nina Le Bert (N)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Florent Ginhoux (F)

Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.

Antonio Bertoletti (A)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.

Qingfeng Chen (Q)

Humanised Mouse Unit, Institute of Molecular and Cell Biology, ASTAR, 61 Biopolis Drive, Singapore 138673, Singapore.
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, 119228, Singapore.

Charles-Antoine Dutertre (CA)

Program in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Singapore Immunology Network, ASTAR, 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648, Singapore.

Classifications MeSH